SK280602B6 - Viacjadrové komplexné zlúčeniny horčíka s aminodik - Google Patents
Viacjadrové komplexné zlúčeniny horčíka s aminodik Download PDFInfo
- Publication number
- SK280602B6 SK280602B6 SK3708-92A SK370892A SK280602B6 SK 280602 B6 SK280602 B6 SK 280602B6 SK 370892 A SK370892 A SK 370892A SK 280602 B6 SK280602 B6 SK 280602B6
- Authority
- SK
- Slovakia
- Prior art keywords
- magnesium
- moles
- preparation
- acid
- compound according
- Prior art date
Links
- 239000011777 magnesium Substances 0.000 title claims abstract description 73
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000002253 acid Substances 0.000 title claims abstract description 14
- 229910052736 halogen Inorganic materials 0.000 title claims abstract description 11
- 150000002367 halogens Chemical class 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 24
- 150000007513 acids Chemical class 0.000 title claims description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 23
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 22
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 20
- 238000002425 crystallisation Methods 0.000 claims abstract description 19
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 19
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004220 glutamic acid Substances 0.000 claims abstract description 16
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 16
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 12
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 229960000259 magnesium asparaginate Drugs 0.000 claims abstract description 6
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 6
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 6
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 6
- ZHYLJCKTXNWNPJ-CEOVSRFSSA-L magnesium;(2s)-2,4-diamino-4-oxobutanoate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC(N)=O.[O-]C(=O)[C@@H](N)CC(N)=O ZHYLJCKTXNWNPJ-CEOVSRFSSA-L 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 6
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000012736 aqueous medium Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 34
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 26
- 230000008025 crystallization Effects 0.000 claims description 18
- -1 magnesium halide Chemical class 0.000 claims description 18
- 239000000376 reactant Substances 0.000 claims description 15
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 208000008167 Magnesium Deficiency Diseases 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims description 3
- 235000004764 magnesium deficiency Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- OZZNZYUTTNWYQX-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC(N)=O OZZNZYUTTNWYQX-DKWTVANSSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 238000010533 azeotropic distillation Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- MYUGVHJLXONYNC-QHTZZOMLSA-L magnesium;(2s)-2-amino-5-hydroxy-5-oxopentanoate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O MYUGVHJLXONYNC-QHTZZOMLSA-L 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910000039 hydrogen halide Inorganic materials 0.000 claims 1
- 239000012433 hydrogen halide Substances 0.000 claims 1
- 150000002680 magnesium Chemical class 0.000 claims 1
- 235000013918 magnesium diglutamate Nutrition 0.000 claims 1
- 229940063886 magnesium glutamate Drugs 0.000 claims 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 10
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 abstract description 9
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 abstract description 9
- 239000001257 hydrogen Substances 0.000 abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-M glutamate Chemical compound [O-]C(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-M 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 239000000047 product Substances 0.000 description 33
- 229940091250 magnesium supplement Drugs 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 14
- 235000012245 magnesium oxide Nutrition 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 12
- 229960002337 magnesium chloride Drugs 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 239000011549 crystallization solution Substances 0.000 description 5
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 5
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000012254 magnesium hydroxide Nutrition 0.000 description 3
- 238000002076 thermal analysis method Methods 0.000 description 3
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 2
- XVPNZUJUCJURHR-NVKWYWNSSA-L C([C@@H](C(=O)[O-])N)C(=O)N.C([C@@H](C(=O)[O-])N)C(=O)N.[Mg+2].Cl Chemical compound C([C@@H](C(=O)[O-])N)C(=O)N.C([C@@H](C(=O)[O-])N)C(=O)N.[Mg+2].Cl XVPNZUJUCJURHR-NVKWYWNSSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000002599 biostatic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- LWWFLOLXKFMKAG-YYXOMIQHSA-J dimagnesium (2S)-2,4-diamino-4-oxobutanoate Chemical compound N[C@@H](CC(N)=O)C(=O)[O-].N[C@@H](CC(N)=O)C(=O)[O-].N[C@@H](CC(N)=O)C(=O)[O-].N[C@@H](CC(N)=O)C(=O)[O-].[Mg+2].[Mg+2] LWWFLOLXKFMKAG-YYXOMIQHSA-J 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- QYOBXHXZJRPWDE-JIZZDEOASA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;chloride Chemical compound [Mg+2].Cl.[O-]C(=O)[C@@H](N)CC([O-])=O QYOBXHXZJRPWDE-JIZZDEOASA-L 0.000 description 1
- LGLXXNHIGIJYQQ-UHFFFAOYSA-L magnesium;dibromide;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Br-].[Br-] LGLXXNHIGIJYQQ-UHFFFAOYSA-L 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS923708A CZ280394B6 (cs) | 1992-12-17 | 1992-12-17 | Vícejaderné komplexní sloučeniny horčíku s aminodikarbonovými kyselinami, halogenem a způsob jejich přípravy a použití |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK370892A3 SK370892A3 (en) | 1995-04-12 |
| SK280602B6 true SK280602B6 (sk) | 2000-04-10 |
Family
ID=5377926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK3708-92A SK280602B6 (sk) | 1992-12-17 | 1992-12-17 | Viacjadrové komplexné zlúčeniny horčíka s aminodik |
Country Status (2)
| Country | Link |
|---|---|
| CZ (1) | CZ280394B6 (cs) |
| SK (1) | SK280602B6 (cs) |
-
1992
- 1992-12-17 SK SK3708-92A patent/SK280602B6/sk unknown
- 1992-12-17 CZ CS923708A patent/CZ280394B6/cs not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SK370892A3 (en) | 1995-04-12 |
| CZ370892A3 (en) | 1994-08-17 |
| CZ280394B6 (cs) | 1996-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3090960B2 (ja) | クレアチン―ピルベート及びその製造方法 | |
| JP2005508379A (ja) | ギ酸ホルメートの製造方法 | |
| US20090253797A1 (en) | Creatine oral supplementation using creatine hydrochloride salt | |
| KR102833111B1 (ko) | 칼슘 알파-케토글루타레이트의 제조 방법 | |
| US9845284B1 (en) | Method of obtaining complex acidic salts of divalent metals and dicarboxylic acids | |
| US6232497B1 (en) | Method for producing alkali metal and alkaline earth metal pyruvates | |
| EP0034172B1 (en) | Mixed salt of valproic acid | |
| JP4796493B2 (ja) | Ｌ−リジン・クエン酸塩結晶 | |
| RU2145602C1 (ru) | Способы получения ламотриджина, промежуточные соединения и способ получения фармацевтической композиции | |
| JPH0587064B2 (cs) | ||
| DK149473B (da) | Fremgangsmaade til fremstilling af aminomethan-phosphonsyrer | |
| SK280602B6 (sk) | Viacjadrové komplexné zlúčeniny horčíka s aminodik | |
| US7301051B2 (en) | Creatine salts and method of making same | |
| KR100343232B1 (ko) | 결정성 파미드론산 이나트륨염 수화물과 그의 제조방법 | |
| EP0045415B1 (en) | Di-l-cysteine l-malate and process for the production thereof | |
| US6342631B1 (en) | Method of producing calcium pyruvates | |
| Kuvaeva et al. | Synthesis of L-ornithine L-aspartate from L-arginine | |
| JP2004091442A (ja) | 水溶性クエン酸マグネシウム含水塩およびその製法 | |
| KR100461572B1 (ko) | Ｌ-카르니틴 칼슘 염과 이의 제조방법 | |
| WO2011107454A1 (en) | Process for the preparation of a polymorph of strontium ranelate | |
| EP0461520A2 (en) | Oxetanocin G anhydride crystals and process for producing the same | |
| CN110950910A (zh) | 一种稳定的米诺膦酸化合物 | |
| CN104530051A (zh) | 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法 | |
| GB2061920A (en) | Aluminum co-precipitate of sucrose sulfate dihydroxyaluminium allantoinate | |
| HU179752B (hu) | Eljárás S-metil-metionin-szulfóniumkloríd előállítására |